UrszulaMasiukiewiczMD

Diabetes, Lipid Metabolism

Physician

Dr. Masiukiewicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
20 York St
Ynhh - West Pavilion, 2nd Floor
New Haven, CT 06510
Phone+1 203-785-4081

Fax+1 203-785-3833

Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1996 - 1998
UMass Chan Medical SchoolResidency, Internal Medicine, 1993 - 1996
Medical University of WarsawClass of 1985

PubMed

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi
The Journal of Clinical Endocrinology and Metabolism. 2023-07-14
17 citations
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Brian S Wojeck, Silvio E Inzucchi, Ian J Neeland, James P Mancuso, Robert Frederich
Sleep & Breathing = Schlaf & Atmung. 2023-05-01
575 citations
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire, Weichung Shih, Francesco Cosentino, Bernard Charbonnel, David Z.I. Cherney
JAMA Cardiology. 2021-02-01

Journal Articles

Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes
Darren K Mcguire, Samuel Dagogo-Jack, Urszula Masiukiewicz, JAMA Cardiology
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Samuel Dagogo-Jack, Urszula Masiukiewicz, Robert Frederich, Darren K Mcguire, The New England Journal of Medicine